Chemkart
102.00
-0.80(-0.78%)
Market Cap₹123.43 Cr
PE Ratio5.13
Company Performance:
1D-0.78%
1M-16.73%
6M-55.83%
1Y-60.69%
5Y-60.69%
View Company Insightsright
More news about Chemkart
13Nov 25
Chemkart India Reports No Deviation in IPO Fund Utilization, Shows Mixed Financial Performance in H1 FY26
Chemkart India Limited, a B2B supplier of raw ingredients for nutritional supplements, reported adherence to its IPO fund utilization plan for the half-year ended September 30, 2025. The company raised Rs. 64.48 crores through its IPO on July 9, 2025. While funds for debt repayment and general corporate purposes were fully utilized, manufacturing facility capex is in early stages. H1 FY26 financial results show a revenue decline of 8.75% and a 35.07% drop in PAT year-over-year, attributed to industry-wide price corrections and reduced demand from a key U.S. customer. However, the company expects stronger growth in the second half with stabilizing prices and resumption of Glycine business.
 no imag found
13Nov 25
Chemkart Reports 8.75% Revenue Decline in H1 FY26 Amid Industry-Wide Price Corrections
Chemkart, a B2B supplier of raw ingredients for nutritional supplements, reported a consolidated revenue of ₹103.23 crores for H1 FY26, down 8.75% year-over-year. EBITDA fell 30.02% to ₹14.16 crores, with margins dropping to 13.71%. PAT decreased by 35.07% to ₹10.15 crores. The decline was attributed to industry-wide price corrections, particularly in Creatine Monohydrate, despite higher sales volumes. The company faced challenges in its amino acid segment due to reduced offtake from a key customer. Chemkart remains optimistic about future prospects, with ongoing construction of a greenfield manufacturing facility at JNPT SEZ and expectations of stronger growth in the second half of the fiscal year.
 no imag found
11Nov 25
Chemkart Reports 14.5% Revenue Growth in H1 FY26, Bolstered by Successful IPO
Chemkart, a nutraceutical raw materials company, reported robust financial results for H1 FY26. Revenue from operations increased by 14.5% to Rs. 10,322.56 lakhs, while profit after tax grew 14.1% to Rs. 1,015.26 lakhs. The company successfully completed its IPO, raising Rs. 6,448 lakhs and strengthening its financial position. Post-IPO net worth rose to Rs. 12,022.41 lakhs, with cash and equivalents at Rs. 4,374.58 lakhs. Chemkart is progressing on its new manufacturing facility at JNPA SEZ and focusing on becoming a fully integrated, export-driven nutraceutical enterprise by FY 2026-27.
 no imag found
11Sept 25
Chemkart India Unveils Robust Growth Strategy and New Manufacturing Facility in Investor Presentation
Chemkart India Limited, a B2B supplier of raw ingredients for nutritional supplements, reported impressive financial growth with a 3-year CAGR of 32.70% in revenue and 64.20% in PAT. The company announced plans for a new greenfield nutraceutical CDMO facility at JNPT SEZ, Maharashtra, focusing on export markets. This facility will offer integrated CDMO operations, including formulation and packaging, with modern technologies and is expected to be operational by FY27. Chemkart currently serves over 500 clients with a diverse portfolio of 150+ ingredients across 10+ product categories.
 no imag found
08Aug 25
Chemkart's Subsidiary EZRM Begins Construction of Advanced Nutraceutical Facility at JNPA SEZ
Chemkart India Limited (CIL) is expanding into manufacturing through its subsidiary, Easy Raw Materials Pvt. Ltd. (EZRM). Construction has begun on a greenfield nutraceutical manufacturing facility at the Jawaharlal Nehru Port Authority Special Economic Zone in Maharashtra. The facility will operate as a Contract Development and Manufacturing Organization, focusing on formulation, packaging, and global exports of health supplements. It will feature advanced technologies like microencapsulation and liposomal delivery systems. Located on a 4,120 sq.m plot leased for 60 years, the facility benefits from proximity to India's largest container port and SEZ policy advantages. The project marks CIL's strategic shift from trading and distribution to becoming an integrated nutraceutical solutions provider.
 no imag found
Chemkart
102.00
-0.80
(-0.78%)
1 Year Returns:-60.69%
Industry Peers
Manorama Industries
1,465.50
(+1.35%)
Orkla
586.95
(+0.09%)
Apis
68.74
(-3.25%)
Krishival Foods
350.00
(+3.87%)
Shri Ahimsa Naturals
279.85
(-0.18%)
Pajson Agro
214.80
(-7.89%)
Freshara Agro Exports
197.95
(-0.10%)
Proventus Agrocom
1,200.00
(0.0%)
Megastar Foods
236.00
(+1.34%)
Shivashrit Foods
140.95
(+4.56%)